NMN vs NAD+: what’s the difference?

NMN and NAD+ are sold for the same goal, keeping the body’s NAD+ levels up as you age, but they are different products with different rules. NAD+ (nicotinamide adenine dinucleotide) is the coenzyme cells use to turn food into energy and to run enzymes involved in DNA repair. NMN (nicotinamide mononucleotide) is one of the building blocks the body turns into NAD+. NMN is sold over the counter as a dietary supplement. NAD+ is sold online mostly as compounded injections and nasal sprays that need a prescription. This guide covers where each stands with the FDA and what the human trials measured, reported as trial results only.

NMN vs NAD+ at a glance

How NMN and NAD+ are related

The body makes NAD+ through several pathways, and NMN sits one step before NAD+ in the main one. The authors of a 2021 trial in Science describe NMN availability as “a rate-limiting factor in mammalian NAD+ biosynthesis” (Yoshino 2021). Nicotinamide riboside (NR) is another precursor sold as a supplement, and in a 6-week crossover trial in healthy middle-aged and older adults it was well tolerated and raised NAD+ metabolism (Martens 2018).

The idea behind NMN is to give the body the raw material to make more NAD+ inside its cells. The idea behind NAD+ injections is to supply NAD+ directly. Neither idea has been tested against the other in people.

NMN’s FDA status: the 2022 position and the 2025 reversal

The FDA’s position on NMN changed twice in three years, according to its own response to a citizen petition:

The reason for the reversal was legal, not medical. A substance studied as a drug can still be a supplement if it was marketed as one first. In 2025 the FDA dropped its earlier requirement that the earlier marketing be lawful, and said it was “aware of evidence that NMN was marketed as a dietary supplement in the United States as early as 2017,” before NMN was authorized for investigation as a drug. The FDA also said that “a product’s safety profile does not determine” the question it was deciding.

What that does and doesn’t mean

NMN can be sold as a dietary supplement. That isn’t an approval. Under the 1994 supplement law, the FDA “does not have the authority to approve dietary supplements before they are marketed” (FDA). A product sold as a supplement may not be marketed to treat, prevent or cure a disease; the FDA says that would make it a drug. Making sure a supplement is safe and labeled correctly is the maker’s job, and the FDA doesn’t check it before sale.

NMN is also still being developed as a drug. A pharmaceutical form called MIB-626 is in a phase 2a trial in 156 adults with diabetic kidney disease (Chandra 2026).

NAD+ injections’ status

No NAD+ drug has ever been FDA-approved. The FDA lists NAD in Category 1 of its 503A categories list, last updated May 14, 2026. Under its interim policy, the FDA does not intend to act against a licensed pharmacy that compounds a Category 1 substance for an individual prescription, as long as the ingredient comes from an FDA-registered source and other conditions are met. That is enforcement discretion, not approval, and it could end if the FDA finalizes its list without NAD. One salt form, beta-NAD disodium salt trihydrate, is in Category 3 and isn’t covered.

Compounded NAD+ isn’t reviewed by the FDA for safety, effectiveness or quality before it is sold. Our NAD+ therapy guide covers the forms clinics sell, and the NAD+ medication page has the full legal note.

What the human trials measured

NMN

These are the randomized and open-label trials of oral NMN we read. Each was small and short.

Scroll sideways to see the full table

Sources: Yoshino 2021, Yi 2023, Pencina 2023, Yamaguchi 2024.

A few things to keep in mind when reading these results. Each trial ran for 10 weeks or less. Raising a level in the blood isn’t the same as changing an outcome a person would notice, and in the Yoshino trial NMN raised NAD+ in blood cells but not in muscle. Several trials had industry ties: three authors of the Yi trial are employees of chemical companies, and the Pencina trial tested a drug candidate from Metro International Biotech, whose staff were co-authors. On safety, the Yi trial reported no safety issues over 60 days and the Pencina trial found adverse events similar to placebo over 28 days. That is not long-term safety data.

NAD+

We found no published controlled trial of NAD+ injections under the skin or NAD+ nasal spray, either for NAD+ levels or for any health outcome. For IV drips, the human data are a small 2019 pilot in which NAD+ levels in plasma did not change during the first 2 hours of a 6-hour infusion, because the body cleared it as fast as it went in (Grant 2019). Our guide to NAD+ injection side effects covers what is known about how drips and injections are tolerated.

What no trial has shown

No trial has compared oral NMN with NAD+ injections, sprays or drips. No trial of NMN or NAD+ has measured aging or lifespan in people, and none has run long enough to tell whether any change in a blood marker lasts or matters.

Cost and where to get each

NMN is sold by supplement brands without a prescription, and we don’t track supplement prices. NAD+ injections need a prescription from a licensed clinician. As of October 2026, PepScribe’s NAD+ injection plan starts at $99 a month with no membership fee; our NAD+ provider rankings compare prices and memberships across the clinics we list, and the longevity hub covers the other treatments they sell.

How to think about the choice

• If you’re considering NMN, you are buying a supplement whose label claims the FDA doesn’t check, backed by small trials that measured blood NAD+ and short-term markers. Tell your clinician you take it, along with every other supplement and medicine.
• If you’re considering NAD+ injections, you are paying for a compounded drug with no FDA review and no published controlled trial. Ask the clinic for its full monthly price, which pharmacy fills the prescription, and which salt form it uses.
• If you’re weighing one against the other, there is no head-to-head evidence. Neither has been shown to slow aging.

The bottom line

NMN and NAD+ aim at the same pathway from different ends. NMN is a supplement the FDA has said may be sold as one since September 29, 2025, with a handful of small trials showing it raises NAD+ in blood over 4 to 10 weeks. NAD+ injections are compounded prescription drugs that pharmacies make under an interim FDA policy, with no published controlled trial of the injections themselves. Neither is FDA-approved to treat anything, and no trial has shown either one slows aging. For a fuller picture of the field, see is longevity medicine legit.